₹25.70
−2.98%NSE close, 16 Nov 2026
+5.94%
Mukka Proteins is a small cap company, listed on NSE under the symbol MUKKA. At ₹25.70 a share, the market values the whole company at ₹771 crore.
In FY26, it reported sales of ₹1,449 crore and a net profit of ₹52 crore, an operating margin of 7.9%.
The market values the company at 9.7 times its profit over the last twelve months and 1.43 times its book value; its return on equity is 14.7% and its borrowings are 1.56 times its equity.
Promoters hold 73.33% of the shares. Foreign institutions hold 1.70%, and domestic institutions, mutual funds among them, 0.20%.
Over the past year the share price has risen 5.8%, and it is 22.8% below its 52-week high.
₹ crore. Consolidated figures.
Mukka Proteins Reports Strong Q2 FY27 PerformanceOman Facility Commences Commercial ProductionU.S. FDA Facility Registration Strengthens Market AccessUSDA NOP Inputs Attestation for Eco Sphere Organic Fertilizer
Revision of terms of investment in Swachha Eco Solutions Private Limited.
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 517 | 257 | 173 | 149 | 303 | 382 | 171 | 245 | 654 | 381 | 490 | 509 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 498 | 225 | 158 | 140 | 262 | 352 | 156 | 224 | 608 | 347 | 442 | 467 |
| Operating profit | 18.9 | 32.2 | 14.1 | 9.6 | 41.4 | 29.2 | 14.6 | 20.7 | 45.4 | 33.9 | 48.0 | 42.3 |
| Operating margin | 3.7% | 12.5% | 8.2% | 6.4% | 13.6% | 7.6% | 8.5% | 8.5% | 7.0% | 8.9% | 9.8% | 8.3% |
| Other income | 6.2 | 4.7 | 2.9 | 3.1 | 5.8 | 4.2 | 2.6 | 6.0 | 4.9 | 15.2 | 1.6 | 9.0 |
| Interest | 6.2 | 6.6 | 8.1 | 8.7 | 10.9 | 10.3 | 11.0 | 12.8 | 14.6 | 15.2 | 16.5 | 17.1 |
| Depreciation | 3.2 | 3.3 | 3.1 | 3.8 | 3.8 | 2.8 | 3.3 | 4.2 | 4.0 | 5.1 | 4.8 | 5.6 |
| Profit before tax | 15.7 | 27.0 | 5.7 | 0.2 | 32.5 | 20.2 | 2.8 | 9.7 | 31.8 | 28.8 | 28.3 | 28.6 |
| Tax | 5.4 | −2.2 | 0.3 | −0.4 | 6.2 | 6.1 | 0.8 | 2.4 | 7.4 | 7.5 | 8.7 | 9.7 |
| Net profit | 10.5 | 27.2 | 4.2 | 2.1 | 26.3 | 13.6 | 1.5 | 5.9 | 23.8 | 20.6 | 18.9 | 16.0 |
| EPS (₹) | 0.48 | 1.20 | 0.14 | 0.07 | 0.88 | 0.45 | 0.05 | 0.20 | 0.79 | 0.69 | 0.63 | 0.53 |
₹ crore, financial years to March.
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|
| From operations | −112 | −111 | 24.6 |
| From investing | −35.0 | −146 | −12.9 |
| From financing | 55.6 | 267 | −1.0 |
| Spent on fixed assets | −20.0 | −121 | −32.1 |
| Free cash flow | −132 | −232 | −7.5 |
Margins, returns, debt, tax and cash.
| Line | FY25 | FY26 |
|---|---|---|
| Net margin | 4.6% | 3.6% |
| Operating margin | 9.4% | 7.9% |
| Return on equity | 10.5% | 10.4% |
| Return on capital employed | 10.8% | 10.0% |
| Return on assets | 4.3% | 3.2% |
| Debt to equity | 1.02 | 1.54 |
| Interest coverage | 2.60 | 2.40 |
| Debt to assets | 0.42 | 0.47 |
| Current ratio | 1.52 | 1.23 |
| Quick ratio | 0.59 | 0.41 |
| Cash ratio | 0.01 | 0.01 |
| Asset turnover | 0.94 | 0.89 |
| Fixed asset turnover | 11.72 | 8.84 |
| Inventory turnover | 1.40 | 1.40 |
| Receivables turnover | 5.00 | 8.00 |
| Gross margin | 23.0% | 19.3% |
| Cash from operations to profit | -241.0% | -214.0% |
| Effective tax rate | 20.6% | 24.7% |
The financial results for the period ended September 30, 2026.
US FDA Registration.
Commencement of commercial production/operations.
Giving corporate guarantee, and security by the Company.
Receipt of a USDA NOP Inputs Attestation.
Update on Acquisition
Schedule of Analyst/institutional Investor Meeting.
Schedule of meet on Monday, 28th September 2026.
Schedule of meet
Schedule of Investor meet to be held on 17th September 2026